Expert Commentary: Cannabis Shows No Meaningful Benefit for Brachial Plexus Injury Pain, But the Question Isn’t Closed

A senior orthopaedic surgeon contextualizes a rigorous negative randomized controlled trial of cannabis-based medicine for neuropathic pain following brachial plexus injury, endorsing its findings while urging the field not to foreclose on broader cannabinoid research for chronic pain conditions.

Why This Matters

Chronic neuropathic pain affects tens of millions of people worldwide and remains among the most difficult clinical problems in musculoskeletal and neurological medicine. Despite growing patient interest in cannabis-based therapies, high-quality evidence for specific pain conditions remains scarce, and negative trials are just as important as positive ones for guiding clinical decisions. When a well-designed randomized trial reports no benefit, expert interpretation of its scope and limits becomes essential to prevent both premature adoption and premature dismissal of an entire therapeutic class.

Clinical Summary

Brachial plexus injuries produce some of the most severe and treatment-resistant neuropathic pain syndromes encountered in orthopaedic and peripheral nerve surgery. Conventional multimodal pharmacotherapy, anchored to the WHO analgesic ladder and supplemented by neuropathic pain agents, often provides incomplete relief. In this context, Kittithamvongs and colleagues conducted a triple-blind crossover randomized controlled trial published in Clinical Orthopaedics and Related Research in 2025, testing whether cannabis oil drops added meaningful analgesia when layered on top of standard drug regimens in men with severe post-traumatic brachial plexus injuries. The mechanistic rationale rests on the known interaction between phytocannabinoids and the endocannabinoid system’s role in pain modulation, particularly in central sensitization pathways relevant to neuropathic states.

The trial enrolled two groups of 14 matched male patients, each receiving a 14-day intervention period with cannabis drops or placebo in crossover fashion, and measured outcomes using the Visual Analogue Scale for nociceptive pain, the DN4 questionnaire for neuropathic pain, and sleep quality assessments. The result was unambiguous for this population: cannabis-based medicine conferred no clinically important benefit as adjuvant therapy. Pierre Hoffmeyer, Emeritus Professor of Orthopaedic Surgery at the University of Geneva, authored an invited CORR Insights commentary endorsing this conclusion but explicitly warning against generalizing the negative finding beyond the studied condition. The commentary highlights the trial’s narrow enrollment (men only, single injury type, short duration) and calls for continued research into cannabinoids for other chronic pain conditions, pain genetics, and novel analgesic development.

Dr. Caplan’s Take

This is a well-framed commentary on an important negative trial, and its central message deserves attention: a null result in one specific population does not invalidate an entire therapeutic category. I see patients with complex neuropathic pain regularly, and many of them ask about cannabis. What I owe them is honesty about what the evidence actually shows, and right now, for brachial plexus injury pain specifically, the best available trial found no added benefit. That is meaningful, and patients deserve to hear it plainly rather than through the distorting lens of either cannabis enthusiasm or reflexive dismissal.

In practice, when a patient with chronic neuropathic pain asks about cannabinoid therapy, I review the condition-specific evidence, which is thin for most diagnoses, and I make sure their conventional regimen is fully optimized before considering adjunctive options. I do not recommend cannabis-based products as first-line or even routine adjunctive therapy for neuropathic pain, but I also do not tell patients the question is settled. What I do is ensure they understand where the science stands, that safety monitoring matters, and that participating in well-designed trials is far more useful than self-experimentation.

Clinical Perspective

This commentary sits at the interpretive stage of a very early research arc. A single small crossover trial, even a well-designed one, establishes an initial data point rather than a definitive conclusion. The commentary’s greatest contribution is drawing the correct inferential boundary: clinicians should not extrapolate these negative findings to other neuropathic or chronic pain populations. It also highlights a meaningful gap in surgical training, namely the limited pharmacological literacy many surgeons bring to the management of patients who are often on complex, multi-drug analgesic regimens. Hoffmeyer’s call for surgeon engagement in pain pharmacology and participation in controlled drug evaluations is well placed and overdue.

From a safety standpoint, cannabis-based medicines carry drug interaction risks with common neuropathic pain agents including gabapentinoids, tricyclic antidepressants, and opioids, particularly through additive CNS depression and cytochrome P450 enzyme modulation. In patients already on multimodal regimens, these interactions are not trivial. Clinicians should ensure that any patient inquiring about cannabinoid adjuncts receives a thorough medication reconciliation and understands that the current evidence base for this specific application does not support routine use. One concrete step clinicians can take now is to document and address cannabinoid inquiries systematically, treating them as an opportunity for evidence-based counseling rather than deferral.

Study at a Glance

Study Type

Invited editorial commentary (CORR Insights) on a triple-blind crossover RCT

Population

Men with severe post-traumatic brachial plexus injuries (RCT); broader chronic pain populations discussed

Intervention

Cannabis oil drops as adjuvant to standard multimodal analgesic therapy (in referenced RCT)

Comparator

Placebo drops in crossover design (in referenced RCT)

Primary Outcomes

VAS (nociceptive pain), DN4 (neuropathic pain), sleep quality

Sample Size

28 patients in two matched groups of 14 (in referenced RCT)

Journal

Clinical Orthopaedics and Related Research

Year

2025

DOI or PMID

Primary article DOI: 10.1097/CORR.0000000000003221

Funding Source

None declared

What Kind of Evidence Is This

This is an invited editorial commentary, which occupies the expert opinion tier of the evidence hierarchy. It contains no original data, performs no systematic literature search, and reflects a single expert’s interpretation of one randomized controlled trial. The most important inference constraint is that its authority is entirely derivative: every claim depends on the quality and accuracy of the referenced RCT, and the commentary cannot independently confirm or refute any clinical hypothesis. It is best understood as interpretive context, not primary evidence.

How This Fits With the Broader Literature

The broader cannabinoid-and-pain literature is marked by heterogeneous study quality, variable formulations and dosing, and condition-specific inconsistencies. Some systematic reviews, including those examining cannabis for cancer pain and multiple sclerosis-related spasticity, have reported modest effects, while others focused on non-cancer chronic pain have found underwhelming or equivocal results. This commentary aligns with a growing consensus that cannabinoid efficacy is likely condition-specific rather than broadly generalizable, and that well-powered trials in defined populations are the only way to resolve the question. The referenced RCT by Kittithamvongs and colleagues is among the first to rigorously test cannabinoids for brachial plexus injury pain specifically, making it a genuinely novel contribution even with its small sample and short duration.

Common Misreadings

The most likely overinterpretation is reading this commentary, or the trial it discusses, as evidence that cannabis does not work for neuropathic pain in general. The trial tested one formulation, at one dose range, over 14 days, in men with one specific injury type, layered on top of existing multimodal therapy. Generalizing a null finding from 28 participants to the entire landscape of chronic neuropathic pain would exceed what the evidence supports. Equally, it would be a misreading to dismiss the negative result as irrelevant simply because the trial was small. Within its defined scope, the trial was methodologically rigorous, and its null finding for this population is credible.

Bottom Line

This commentary responsibly endorses a well-designed trial’s finding that cannabis-based medicine added no meaningful pain relief for brachial plexus injury neuropathic pain. It does not establish that cannabinoids are ineffective for chronic pain broadly. It offers clinicians a model for interpreting negative trials without overcorrecting, and it reinforces that surgeon engagement in pain pharmacology and precision medicine research is both necessary and overdue.

References

1. Kittithamvongs P, et al. Cannabis-based medicine as adjuvant therapy for neuropathic pain in brachial plexus injuries: a triple-blind crossover randomized controlled trial. Clin Orthop Relat Res. 2025. DOI: 10.1097/CORR.0000000000003221
2. Hoffmeyer P. CORR Insights: Cannabis-based medicine as adjuvant therapy for neuropathic pain in brachial plexus injuries. Clin Orthop Relat Res. 2025.